18 research outputs found
ARTICLE IN PRESS Türk Psikiyatri Dergisi 2010; Turkish Journal of Psychiatry Relati ves' Knowledge and Opinions About Schizophrenia
Short-Term Outcomes of Patent Ductus Arteriosus Closure With New Occlutech (R) Duct Occluder: A Multicenter Study
WOS: 000384919800011PubMed ID: 27090770Aim: Over the past 2 decades, transcatheter occlusion of patent ductus arteriosus (PDA) with coils and the duct occluders evolved to be the procedure of choice. A new device, the Occlutech PDA1 occluder (ODO) device has been designed. Herein, we aimed to evaluate the characteristics and short-term results of patients who underwent transcatheter closure of PDA using the ODO. Methods: We reviewed the clinical records of 60 patients from different centers in Turkey between December 2013 and January 2016. The medical records were reviewed for demographic characteristics and echocardiographic findings. Device size was selected on the narrowest diameter of PDA. Results: The median patient age was 2.5 years (6 months-35 years), and median PDA diameter was 2.5mm (1.2-11 mm). Fifty-eight of 60 patients (96.6%) had successful ODO implantation. The occlusion rates were 37/58 (63.7%) at the end of the procedure, 51/58 (87.9%) at 24-48 hours post-procedure, and 57/58 (98.2%) on echocardiography at a median follow-up of 7.6 months. Conclusion: Our results indicate that transcatheter closure of PDA using the ODO is effective. Larger studies and longer follow-up are required to assess whether its shape and longer length make it superior to other duct occluders in large, tubular, or window-type ducts
Certolizumab Pegol Treatment in Three Patients With Takayasu Arteritis
Although glucocorticoids are the mainstay of treatment in Takayasu
arteritis (TA), anti-tumor necrosis factor agents are other treatment
options in refractory disease. The onset of TA is generally observed in
females of reproductive age. Certolizumab pegol (CZP) lacks a fragment
crystallizable region and this gives advantage of minimal transfer
through the placenta, which makes CZP a safer option in pregnancy.
Although there are case reports and trials about use of infliximab,
etanercept, and adalimumab in TA, there are scarce data about use of
CZP. In this article, we present three TA cases treated with CZP. While
two patients benefited from CZP, one patient was refractory to CZP
Comorbidity and long-term outcome in patients with congenital heart block and their siblings exposed to Ro/SSA autoantibodies in utero
EFFECT OF DIETARY FAT ON OBESITY AND METABOLIC SYNDROME IN SMOKERS: A CROSS-SECTIONAL STUDY
COVID-19 in Familial Mediterranean Fever: Clinical Course and Complications Related to Primary Disease.
OBJECTIVES: To evaluate the impact of familial Mediterranean fever (FMF) features on the clinical course and outcomes of coronavirus disease 2019 (COVID-19) and clinical course of FMF after COVID-19. METHODS: Consecutive FMF patients with COVID-19 were enrolled from three referral hospitals. Clinical features of FMF and detailed COVID-19 information were obtained from patient interviews and medical records. RESULTS: Seventy-three FMF patients were included in the study. 94.5% of patients had clinical symptoms of COVID-19. We found 24.7% hospitalization, 12.3% respiratory support, 4.1% intensive care unit admission, 6.8% complication, and 1.4% mortality rate in patients. The risk factors of hospitalization for respiratory support were male gender [OR: 7.167 (95% CI: 1.368–37.535)], greater age [OR: 1.067 (95% CI: 1.016–1.121)], and non-adherence to colchicine treatment before the infection [OR: 7.5 (95% CI: 1.348–41.722)]. One-third of patients had reported attacks after COVID-19. The patterns of triggered attacks were fever, peritonitis, pleuritis, transient arthritis, chronic knee mono-arthritis, and protracted febrile myalgia. CONCLUSIONS: FMF characteristics were not associated with worse outcomes of COVID-19. Colchicine non-adherence was the risk factor of hospitalization for oxygen support. The rate of FMF attacks after COVID-19 is prominently increased, with some of them being protracted and destructive
Short-Term Outcomes of Patent Ductus Arteriosus Closure With New Occlutech (R) Duct Occluder: A Multicenter Study
Aim: Over the past 2 decades, transcatheter occlusion of patent ductus arteriosus (PDA) with coils and the duct occluders evolved to be the procedure of choice. A new device, the Occlutech PDA1 occluder (ODO) device has been designed. Herein, we aimed to evaluate the characteristics and short-term results of patients who underwent transcatheter closure of PDA using the ODO